These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 25359385)

  • 21. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
    Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac and vascular atrogin-1 mRNA expression is not associated with dexamethasone efficacy in the monocrotaline model of pulmonary hypertension.
    Paffett ML; Channell MM; Naik JS; Lucas SN; Campen MJ
    Cardiovasc Toxicol; 2012 Sep; 12(3):226-34. PubMed ID: 22311109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension.
    Falcão-Pires I; Gonçalves N; Henriques-Coelho T; Moreira-Gonçalves D; Roncon-Albuquerque R; Leite-Moreira AF
    Am J Physiol Heart Circ Physiol; 2009 Jun; 296(6):H2007-14. PubMed ID: 19346461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration.
    Bueno-Beti C; Sassi Y; Hajjar RJ; Hadri L
    Methods Mol Biol; 2018; 1816():233-241. PubMed ID: 29987824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ca
    Sabourin J; Boet A; Rucker-Martin C; Lambert M; Gomez AM; Benitah JP; Perros F; Humbert M; Antigny F
    J Mol Cell Cardiol; 2018 May; 118():208-224. PubMed ID: 29634917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monocrotaline induce pulmonary hypertension in animal models].
    Alexandru B; Bogdan MA
    Pneumologia; 2001; 50(2):85-9. PubMed ID: 11584679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension.
    Uzzaman M; Honjo H; Takagishi Y; Emdad L; Magee AI; Severs NJ; Kodama I
    Circ Res; 2000 Apr; 86(8):871-8. PubMed ID: 10785509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of erectile function in monocrotaline-treated pulmonary hypertensive rats.
    Gur S; Kadowitz PJ; Thammasitboon S; Lasky JA; Hellstrom WJ
    J Androl; 2009; 30(5):495-504. PubMed ID: 19201699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tachykinin dysfunction attenuates monocrotaline-induced pulmonary hypertension.
    Chen MJ; Lai YL
    Toxicol Appl Pharmacol; 2003 Mar; 187(3):178-85. PubMed ID: 12662901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pyrrolidine dithiocarbamate attenuates the development of monocrotaline-induced pulmonary arterial hypertension.
    Yavuz T; Uzun O; Macit A; Comunoglu C; Yavuz O; Silan C; Yuksel H; Yildirim HA
    Pathol Res Pract; 2013 May; 209(5):302-8. PubMed ID: 23582365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stage-dependent changes in membrane currents in rats with monocrotaline-induced right ventricular hypertrophy.
    Lee JK; Kodama I; Honjo H; Anno T; Kamiya K; Toyama J
    Am J Physiol; 1997 Jun; 272(6 Pt 2):H2833-42. PubMed ID: 9227563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
    Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
    Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endostatin is protective against monocrotaline-induced right heart disease through the inhibition of T-type Ca(2+) channel.
    Imoto K; Kumatani S; Okada M; Yamawaki H
    Pflugers Arch; 2016 Jul; 468(7):1259-1270. PubMed ID: 27023352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system.
    Schultze AE; Roth RA
    J Toxicol Environ Health B Crit Rev; 1998; 1(4):271-346. PubMed ID: 9776954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total ginsenosides inhibit the right ventricular hypertrophy induced by monocrotaline in rats.
    Qin N; Gong QH; Wei LW; Wu Q; Huang XN
    Biol Pharm Bull; 2008 Aug; 31(8):1530-5. PubMed ID: 18670084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats.
    Ishikawa M; Sato N; Asai K; Takano T; Mizuno K
    Circ J; 2009 Dec; 73(12):2337-41. PubMed ID: 19822980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous production of ghrelin and beneficial effects of its exogenous administration in monocrotaline-induced pulmonary hypertension.
    Henriques-Coelho T; Correia-Pinto J; Roncon-Albuquerque R; Baptista MJ; Lourenço AP; Oliveira SM; Brandão-Nogueira A; Teles A; Fortunato JM; Leite-Moreira AF
    Am J Physiol Heart Circ Physiol; 2004 Dec; 287(6):H2885-90. PubMed ID: 15331358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)- 4-oxobut-2-enoate-sodium (PD 155080).
    Brunner F; Wölkart G; Haleen S
    J Pharmacol Exp Ther; 2002 Feb; 300(2):442-9. PubMed ID: 11805203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.